ClinicalTrials.Veeva

Menu
R

Retina Group of New England | Waterford, CT

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Ranibizumab
KSI-301
Aflibercept
Faricimab
ABP 938
APL-2
RG7774
Lampalizumab
Eylea®

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 21 total trials

A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm (PAVILION)

Study GR41675 is a Multicenter, Randomized Study in Participants with Diabetic Retinopathy (DR) Without Center-Involved Diabetic Macular Edema (CI-DM...

Active, not recruiting
Diabetic Retinopathy
Drug: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab
Drug: Intravitreal Ranibizumab 0.5 mg Injection

This study is researching aflibercept high dose (HD), referred to as "study drug", with an experimental dosing regimen. The study is focused on parti...

Enrolling
Neovascular Age-Related Macular Degeneration
Diabetic Macular Edema
Drug: Aflibercept 8 mg

This study will assess corneal endothelial cells in participants with nAMD treated with PDS refilled every 24 weeks (Q24W).

Enrolling
Neovascular Age-related Macular Degeneration
Device: SUSVIMO PDS Implant
Drug: LUCENTIS (ranibizumab injection)
Locations recently updated

This study is researching experimental (study) drugs called pozelimab and cemdisiran. The study is focused on participants who have geographic atroph...

Enrolling
Age-related Macular Degeneration (AMD)
Geographic Atrophy (GA)
Drug: Placebo
Drug: Pozelimab

This study will evaluate the efficacy, safety, and pharmacokinetics of the PDS with Ranibizumab in participants with DME when treated every 24 weeks...

Active, not recruiting
Diabetic Macular Edema
Drug: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab
Drug: Ranibizumab refill exchange

This study will evaluate the long-term safety and tolerability of the Port Delivery System with ranibizumab (PDS) (100 mg/mL) in participants with ne...

Enrolling
Neovascular Age-Related Macular Degeneration
Drug: PDS Implant with Ranibizumab 100 mg/mL

Trial sponsors

Roche logo
Kodiak Sciences logo
Regeneron Pharmaceuticals logo
Amgen logo
A
Genentech logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems